Why the study?
What is the prevalence and clinical implication of pathogenic gene variants in patients with dilated cardiomyopathy?
Population
Patients with dilated cardiomyopathy, including those with an established nongenetic risk factor or a…
Design
Review
Authors
Loading...
May support genetic testing in nonfamilial DCM; leaves open whether variant identification improves outcomes or management.
What is the prevalence and clinical implication of pathogenic gene variants in patients with dilated cardiomyopathy?
Pathogenic gene variants are present in 20% of DCM patients even with nonfamilial or nongenetic risk factors, suggesting a broader role for genetic testing to identify patients at risk for arrhythmias and adverse outcomes.
Verdonschot et al. (2020) studied this question.